DOCSLIB.ORG

The Clinical Spectrum of Hereditary Nephritis Principal Discussant: JEAN-PIERRE GRUNFELD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Clinical Spectrum of Hereditary Nephritis Principal Discussant: JEAN-PIERRE GRUNFELD View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 27 (1985), pp. 83—92 NEPHROLOGY FORUM The clinical spectrum of hereditary nephritis Principal discussant: JEAN-PIERRE GRUNFELD Hôpital Necker, Paris, France sion (180/130 mm Hg) and chronic renal failure (serum creatinine 3.1 Editors mgldl). Protein excretion, 3 g/day, was associated with microscopic JORDANJ.COHEN hematuria. Audiometric testing was normal, and ophthalmic examina- tion did not reveal lenticonus or perimacular changes. JOHN 1.HARRINGION The patient belongs to a kindred with Alport's syndrome (Fig. 2). His JEROME P.KASSIRER father, who is 63 years of age, has undergone hemodialysis for 10 years. NIcoiAos E.MADIAS He has severe perceptive deafness. Three males and one female in the kindred died from renal failure. One cousin (IV 1, Fig. 2) had a renal Managing Editor transplant in 1972 at age 39 and has stable renal function at present. Renal biopsy in another affected cousin (IV 2, Fig. 2) disclosed CHERYL J.ZUSMAN characteristic ultrastructural changes of Alport's syndrome in the glomerular basement membrane. Now, one year later, the patient's blood pressure is well controlled MichaelReese Hospital and Medical Center with 200 mg of metoprolol per day, and serum creatinine is 4.5 mgldl. Universityof Chicago Pritzker Sc/iou! of Medicine and Discussion New England Medical Center Tufts University School of Medicine DR. JEAN-PIERRE GRUNFELD (Département de Néphro/ogie, Hôpital Necker, Paris, France): Various heredofamilial dis- eases involve the kidney (Table 1). The first two groups in Table 1 consist of disorders in which the renal disease is the predomi- Case presentations nant feature of the illness. Groups 3 and 4 are more heteroge- Patient 1. A 30-year-old woman had been referred to the Department neous diseases that affect several organs, including the kidneys. of Nephrology of Hôpital Necker at age 19 for evaluation of proteinuria Group 5 comprises isolated and poorly classified cases of and microscopic hematuria. At that time, blood pressure was 110/60 mm Hg and urinary protein excretion ranged from 2.7 to 5.7 g/24 hr. hereditary renal diseases [1—4]. In my experience, the frequen- Urine erythrocyte count was 500,000/mm. Serum protein and albumin cy of hereditary renal disease is often underestimated: many levels were 5.7 and 3.1 g/dl, respectively. Creatinine clearance was 95 cases are undetected or unreported because they lack either mI/mm and serum creatinine 0.9 mg/dl. Percutaneous renal biopsy specific extrarenal defects or renal pathologic changes. Indeed, showed mild interstitial fibrosis associated with ischemic glomerular Waldherr, who focused attention on familial diseases with changes, but no foam cells or glomerular segmental lesions were found. Electron microscopy revealed a thickened glomerular basement mem- prominent glomerular involvement, found lesions compatible brane with splitting and splintering of the lamina densa. with familial glomerular disease in 7% of adults with glomerular A diagnosis of hereditary nephritis was made, based on the following lesions on renal biopsy specimens and in 13% of patients with data. (1) The 20-year-old sister of the patient had end-stage renal failure end-stage renal failure secondary to glomerulonephritis [51. necessitating regular hemodialysis, and she subsequently received a Thelist in Table I is not all-inclusive. I have omitted renal cadaveric renal transplant. (2) Both the patient and her sister had bilateral perceptive deafness, bilateral anterior lenticonus, and retinal diseases in which familial aggregation can occur, such as IgA perimacular changes. No other member of the kindred was affected mesangial glomerulopathy (Berger's disease), lupus nephritis, (Fig. 1). The parents were first-degree cousins. and vesicoureteral reflux complicated by renal scarring. The At age 21, the patient became pregnant. The nephrotic syndrome discussion today will concern itself with the first group in Table worsened and renal failure developed during the pregnancy; serum creatinine increased from 1.0 to 2.3 mg/dl. Blood pressure did not1, that is, hereditary nephritis, and most particularly, progres- increase. She delivered a 2.7 kg boy at 41 weeks gestation. Subsequent- sive hereditary nephritis. Both case presentations illustrate ly her renal function decreased progressively. At age 26, regular many features of these syndromes. hemodialysis was initiated, and at age 29 she received a cadaveric renal The existence of hereditary or familial renal diseases was transplant. One year later, creatinine clearance was 87 ml/min; norecognized at the end of the 19th century. In 1927, Alport proteinuria was found. The patient's child is now 8 years old and has no extended the study of a family that first had been investigated urinary symptoms. Patient 2. A 35-year-old man was referred for evaluation of hyperten- by others in 1902. His report drew attention to the syndrome of hereditary nephritis and perceptive deafness that now bears his name [6]. In 1968 the original family was retraced, but no new Presentation of the Forum is made possible by grants from Smith Kline cases had appeared since Alport's report [7]. As stated by & French Laboratories, CIBA Pharmaceutical Company, and GEIGY Crawfurd and Toghill, "Alport's original family has rid itself of Pharmaceuticals. Alport's disease" [7]! © 1985 by the International Society of Nephrology The following definitions have evolved and will be useful in 83 84 Nephrology Forum before age 9, and 5 other boys developed ESRD between ages 9 and 16 [15]. In adults, ESRD develops between ages 20 and 40 [17, 19] but can appear even after age 50. I will discuss later the various rates of progression to ESRD. Alport's syndrome represents approximately 3% of the causes of ESRD in the periodic European Dialysis and Transplantation Registry re- ports. In Utah, approximately 5% of all male patients with ESRD were considered to have hereditary nephritis [16]. Hearing loss. Nerve deafness is one of the hallmarks of Alport's syndrome. The neurogenic hearing impairment is bilateral and may lead either to clinically evident deafness or to Fig. 1. Pedigree of Family 1. Symbols are: Li consanguineous marriage; / propositus;affected female; affected male; • neural a mild defect predominating in the middle or high tone range. hearing loss; () age at death or "renal death." Because subclinical hearing impairment may exist, audiometric testing is required to detect all affected individuals. Audiometry rarely has been performed in all members of affected kindreds, discussing these heredofamilial disorders. (1) Alport's syn-and for this reason the true incidence of neural hearing loss is drome is characterized by renal disease that progresses to renalnot known. We do know, however, that hearing loss varies failure and by neural hearing loss in the patient or other familyfrom one kindred to another. members. (2) Hereditary nephritis without nerve deafness is The hearing defect often can be detected before age 10 [15]. characterized only by progressive renal disease in the patient orIts frequency is high, at least in boys. In the pediatric series of other family members [8]; diagnosis of this disease is difficult inGubler et al [15], 34 of 42 boys had hearing defects, whereas the absence of a strong family history. (3) Familial benignonly 3 of 16 girls had hearing loss. In children, serial audiome- hematuria is characterized by renal disease without renal fail-tric tests may show progressive hearing loss, necessitating a ure; nerve deafness is absent in the patient and other familyhearing aid [15, 201. In contrast, hearing impairment generally members. Only a few kindreds with this disorder have beendoes not progress in adults. Although hearing improvement has reported [9—13]. As I will discuss later, the specificity andbeen described after successful renal transplantation [21], this independence of these syndromes are not totally established,change may be nonspecific because deafness attributable to but these definitions provide a convenient clinical classificationuremia also may improve after renal transplantation [22]. for analyzing these conditions. The pathologic lesions responsible for the hearing defect are not well delineated. Although some investigators have identi- Clinical presentation of A/port's syndrome fied a variety of lesions [23], others have not found any Renal symptoms. As noted even in the first description of thissignificant changes. Johnsson and Arenberg detected abnormal- disease, hematuria is the most frequent initial symptom inities of the temporal bones, strial atrophy, vacuolation of the children [6, 14]. Hematuria is either microscopic or gross,spiral ligament, and a predominance of sensory cell degenera- recurrent or not. It can appear at birth or within the first fewtion [24]. These abnormalities are not specific, however. It months of life [151. Of 58 affected children reported by Gubler etshould be noted that strial atrophy is commonly associated with al, manifestations appeared during the first year of life in 8, 32sensorineural degeneration, such as that occurring in various children had gross hematuria, and in 25 the first episodeforms of hereditary deafness and in noise exposure. In addition, occurred before the age of 5. Gross hematuria recurred in 26 butearly childhood deafness is a common feature in a great variety usually disappeared after age 15 [15]. Gross hematuria is quiteof hereditary syndromes, only some of which include renal infrequent in adults, but microscopic hematuria persists and redinvolvement [25—32]. blood cell casts are frequent [16]. Proteinuria is usually absent Ocular defects. Ocular disorders, first described by Sohar in or minimal in young children but it increases with age. The1956 [33], mainly involve the lens. Bilateral anterior lenticonus nephrotic syndrome develops in 30% to 40% of the patients [15,has been considered the most specific eye abnormality in 17]; its incidence peaks between ages 14 and 20. Alport' s syndrome [34].
Load more

Recommended publications
  • The Counsyl Foresight™ Carrier Screen
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series
    DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F.
    [Show full text]
  • Its Place Among Other Genetic Causes of Renal Disease
    J Am Soc Nephrol 13: S126–S129, 2002 Anderson-Fabry Disease: Its Place among Other Genetic Causes of Renal Disease JEAN-PIERRE GRU¨ NFELD,* DOMINIQUE CHAUVEAU,* and MICHELINE LE´ VY† *Service of Nephrology, Hoˆpital Necker, Paris, France; †INSERM U 535, Baˆtiment Gregory Pincus, Kremlin- Biceˆtre, France. In the last two decades, decisive advances have been made in Nephropathic cystinosis, first described in 1903, is an auto- the field of human genetics, including renal genetics. The somal recessive disorder characterized by the intra-lysosomal responsible genes have been mapped and then identified in accumulation of cystine. It is caused by a defect in the transport most monogenic renal disorders by using positional cloning of cystine out of the lysosome, a process mediated by a carrier and/or candidate gene approaches. These approaches have that remained unidentified for several decades. However, an been extremely efficient since the number of identified genetic important management step was devised in 1976, before the diseases has increased exponentially over the last 5 years. The biochemical defect was characterized in 1982. Indeed cysteam- data derived from the Human Genome Project will enable a ine, an aminothiol, reacts with cystine to form cysteine-cys- more rapid identification of the genes involved in the remain- teamine mixed disulfide that can readily exit the cystinotic ing “orphan” inherited renal diseases, provided their pheno- lysosome. This drug, if used early and in high doses, retards the types are well characterized. We have entered the post-gene progression of cystinosis in affected subjects by reducing intra- era. What is/are the function(s) of these genes? What are the lysosomal cystine concentrations.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • X Inactivation, Female Mosaicism, and Sex Differences in Renal Diseases
    BRIEF REVIEW www.jasn.org X Inactivation, Female Mosaicism, and Sex Differences in Renal Diseases Barbara R. Migeon McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University, Baltimore Maryland ABSTRACT A good deal of sex differences in kidney disease is attributable to sex differences expressed only in the testes, they have to do in the function of genes on the X chromosome. Males are uniquely vulnerable to with testicular function and fertility. With mutations in their single copy of X-linked genes, whereas females are often mosaic, one X chromosome, males have only a sin- having a mixture of cells expressing different sets of X-linked genes. This cellular gle copy of their X-linked genes. mosaicism created by X inactivation in females is most often advantageous, pro- On the other hand, even though fe- tecting carriers of X-linked mutations from the severe clinical manifestations seen males have two copies of these genes, in males. Even subtle differences in expression of many of the 1100 X-linked genes both are not expressed in the same cell. may contribute to sex differences in the clinical expression of renal diseases. Only one X is programmed to work in each diploid somatic cell. All of the other J Am Soc Nephrol 19: 2052–2059, 2008. doi: 10.1681/ASN.2008020198 X chromosomes in the cell become inac- tive during fetal development. Briefly, compensation for X dosage in our spe- Although being female conveys a protec- with normal kidney function. This re- cies is accomplished by a process that en- tive effect on the progression of chronic view addresses the genetic and epigenetic sures only a single X is active in both renal disease, the basis for this sex differ- programs that contribute to the sex dif- sexes.
    [Show full text]
  • Essential Genetics 5
    Essential genetics 5 Disease map on chromosomes 例 Gaucher disease 単一遺伝子病 天使病院 Prader-Willi syndrome 隣接遺伝子症候群，欠失が主因となる疾患 臨床遺伝診療室 外木秀文 Trisomy 13 複数の遺伝子の重複によって起こる疾患 挿画 Koromo 遺伝子の座位あるいは欠失等の範囲を示す Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 1 Gaucher disease Chromosome 1q21.1 1p36 deletion syndrome deletion syndrome Adrenoleukodystrophy, neonatal Cardiomyopathy, dilated, 1A Zellweger syndrome Charcot-Marie-Tooth disease Emery-Dreifuss muscular Hypercholesterolemia, familial dystrophy Hutchinson-Gilford progeria Ehlers-Danlos syndrome, type VI Muscular dystrophy, limb-girdle type Congenital disorder of Insensitivity to pain, congenital, glycosylation, type Ic with anhidrosis Diamond-Blackfan anemia 6 Charcot-Marie-Tooth disease Dejerine-Sottas syndrome Marshall syndrome Stickler syndrome, type II Chronic granulomatous disease due to deficiency of NCF-2 Alagille syndrome 2 Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 2 Epiphyseal dysplasia, multiple Spondyloepimetaphyseal dysplasia Brachydactyly, type D-E, Noonan syndrome Brachydactyly-syndactyly syndrome Peters anomaly Synpolydactyly, type II and V Parkinson disease, familial Leigh syndrome Seizures, benign familial Multiple pterygium syndrome neonatal-infantile Escobar syndrome Ehlers-Danlos syndrome, Brachydactyly, type A1 type I, III, IV Waardenburg syndrome Rhizomelic chondrodysplasia punctata, type 3 Alport syndrome, autosomal recessive Split-hand/foot malformation Crigler-Najjar
    [Show full text]
  • Genetic Testing Services and Support, from Preconception to Prenatal the Way Many Think About Carrier Screening Is Changing
    Genetic testing services and support, from preconception to prenatal The way many think about carrier screening is changing. Carrier screening, once thought to be a test primarily for specific ethnic groups, is now often recommended for every patient. The American Congress of Obstetricians and Gynecologists (ACOG) recently updated its recommendations, stating that carrier screening for spinal muscular atrophy (SMA), in addition to cystic fibrosis (CF), "should be offered to all women who are considering pregnancy or are currently pregnant."7 COMPREHENSIVE, VERSATILE, COVERING WHAT MATTERS Inheritest® provides carrier screening for more than 110 severe disorders that can cause cognitive or physical impairment and/or require surgical or medical intervention. Selected to focus on severe disorders of childhood onset, and to meet ACOG and the American College of Medical Genetics and Genomics (ACMG) criteria, many of the disorders share a recommendation for early intervention. Inheritest offers multiple panels to suit the diverse needs of your patients: Focuses on mutations for CF, SMA, and fragile X syndrome, with the following carrier risks: CORE PANEL CF: as high as 1 in 248 SMA: as high as 1 in 479 Fragile X syndrome: approximately 3 GENES (varies by ethnicity) (varies by ethnicity) 1 in 259 females (all ethnicities)10 SOCIETY-GUIDED PANEL Includes mutations for more than 13 disorders listed in ACOG and/or ACMG recommendations 14 GENES ASHKENAZI JEWISH Enhanced panel includes mutations for more than 40 disorders relevant to patients of Ashkenazi PANEL 48 GENES Jewish descent COMPREHENSIVE Includes mutations for more than 110 disorders across 144 different genes—includes all disorders in PANEL 144 GENES Core, Society-guided, and Ashkenazi Jewish panels THE CASE FOR EXPANDED CARRIER SCREENING While some providers may only screen for CF or select screening based on ethnicity, the case for more comprehensive screening is becoming clear.
    [Show full text]
  • Inheritest 500 PLUS
    Inheritest® 500 PLUS 525 genes Specimen ID: 00000000010 Container ID: H0651 Control ID: Acct #: LCA-BN Phone: SAMPLE REPORT, F-630049 Patient Details Specimen Details Physician Details DOB: 01/01/1991 Date Collected: 08/05/2019 12:00 (Local) Ordering: Age (yyy/mm/dd): 028/07/04 Date Received: 08/06/2019 Referring: Gender: Female Date Entered: 08/06/2019 ID: Patient ID: 00000000010 Date Reported: 08/21/2019 15:29 (Local) NPI: Ethnicity: Unknown Specimen Type: Blood Lab ID: MNEGA Indication: Carrier screening Genetic Counselor: None SUMMARY: POSITIVE POSITIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Spinal muscular atrophy AT RISK AT RISK to be a silent carrier (2+0). For ethnic-specific risk (SMN1) 2 copies of SMN1; positive for revisions see Methods/Limitations. Genetic counseling is NMID: NM_000344 c.*3+80T>G SNP recommended. Risk: AT INCREASED RISK FOR AFFECTED PREGNANCY. See Additional Clinical Information. NEGATIVE RESULTS DISORDER (GENE) RESULTS INTERPRETATION Cystic fibrosis NEGATIVE This result reduces, but does not eliminate the risk to be a (CFTR) carrier. NMID: NM_000492 Risk: NOT at an increased risk for an affected pregnancy. Fragile X syndrome NEGATIVE: Not a carrier of a fragile X expansion. (FMR1) 29 and 36 repeats NMID: NM_002024 Risk: NOT at an increased risk for an affected pregnancy. ALL OTHER DISORDERS NEGATIVE This result reduces, but does not eliminate the risk to be a carrier. Risk: The individual is NOT at an increased risk for having a pregnancy that is affected with one of the disorders covered by this test. For partner's gene-specific risks, visit www.integratedgenetics.com.
    [Show full text]
  • A Model of Autosomal Recessive Alport Syndrome in English Cocker Spaniel Dogs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 54 (1998), pp. 706–719 A model of autosomal recessive Alport syndrome in English cocker spaniel dogs GEORGE E. LEES,R.GAYMAN HELMAN,CLIFFORD E. KASHTAN,ALFRED F. MICHAEL,LINDA D. HOMCO, NICHOLAS J. MILLICHAMP,YOSHIFUMI NINOMIYA,YOSHIKAZU SADO,ICHIRO NAITO, and YOUNGKI KIM Texas Veterinary Medical Center, Texas A&M University, College Station, Texas, Oklahoma Animal Disease Diagnostic Laboratory, Oklahoma State University, Stillwater, Oklahoma, and Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA; Department of Molecular Biology and Biochemistry, Okayama University Medical School, Okayama, and Divisions of Immunology and Ultrastructural Biology, Shigei Medical Research Institute, Okayama, Japan A model of autosomal recessive Alport syndrome in English cause progressive glomerular disease [1–3]. In humans with cocker spaniel dogs. Alport syndrome (AS), the nephropathy is frequently asso- Background. Dogs with naturally occurring genetic disorders of basement membrane (type IV) collagen may serve as animal ciated with sensorineural hearing loss and ocular abnormal- models of Alport syndrome. ities. Distinctive ultrastructural changes in glomerular base- Methods. An autosomal recessive form of progressive heredi- ment membranes (GBM) of affected individuals is a tary nephritis (HN) was studied in 10 affected, 3 obligate carrier, prominent characteristic of these disorders [1–3]. and 4 unaffected English cocker spaniel (ECS) dogs. Clinical, In humans AS usually is X-linked, resulting from muta- pathological, and ultrastructural features of the disease were a characterized. Expression of basement membrane (BM) proteins tions in the COL4A5 gene, which encodes the 5 chain of was examined with an immunohistochemical technique using type IV collagen [1, 4].
    [Show full text]
  • EUROCAT Syndrome Guide
    JRC - Central Registry european surveillance of congenital anomalies EUROCAT Syndrome Guide Definition and Coding of Syndromes Version July 2017 Revised in 2016 by Ingeborg Barisic, approved by the Coding & Classification Committee in 2017: Ester Garne, Diana Wellesley, David Tucker, Jorieke Bergman and Ingeborg Barisic Revised 2008 by Ingeborg Barisic, Helen Dolk and Ester Garne and discussed and approved by the Coding & Classification Committee 2008: Elisa Calzolari, Diana Wellesley, David Tucker, Ingeborg Barisic, Ester Garne The list of syndromes contained in the previous EUROCAT “Guide to the Coding of Eponyms and Syndromes” (Josephine Weatherall, 1979) was revised by Ingeborg Barisic, Helen Dolk, Ester Garne, Claude Stoll and Diana Wellesley at a meeting in London in November 2003. Approved by the members EUROCAT Coding & Classification Committee 2004: Ingeborg Barisic, Elisa Calzolari, Ester Garne, Annukka Ritvanen, Claude Stoll, Diana Wellesley 1 TABLE OF CONTENTS Introduction and Definitions 6 Coding Notes and Explanation of Guide 10 List of conditions to be coded in the syndrome field 13 List of conditions which should not be coded as syndromes 14 Syndromes – monogenic or unknown etiology Aarskog syndrome 18 Acrocephalopolysyndactyly (all types) 19 Alagille syndrome 20 Alport syndrome 21 Angelman syndrome 22 Aniridia-Wilms tumor syndrome, WAGR 23 Apert syndrome 24 Bardet-Biedl syndrome 25 Beckwith-Wiedemann syndrome (EMG syndrome) 26 Blepharophimosis-ptosis syndrome 28 Branchiootorenal syndrome (Melnick-Fraser syndrome) 29 CHARGE
    [Show full text]